Related references
Note: Only part of the references are listed.Signaling pathways as therapeutic targets in biliary tract cancer
Jennifer Yang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Role of the Notch signaling in cholangiocarcinoma
Antonio Cigliano et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Philip Morgan et al.
PHARMACOECONOMICS (2017)
Update on cholangiocarcinoma: potential impact of genomic studies on clinical management
Dirk Walter et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2017)
Intrahepatic cholangiocarcinoma: current management and emerging therapies
Amir A. Rahnemai-Azar et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets
Douglas V. N. P. Oliveira et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Analysis of origin and protein-protein interaction maps suggests distinct oncogenic role of nuclear EGFR during cancer evolution
Ainur Sharip et al.
JOURNAL OF CANCER (2017)
Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma
Finn Ole Larsen et al.
ACTA ONCOLOGICA (2016)
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
Francesco Leone et al.
CANCER (2016)
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini et al.
CLINICAL CANCER RESEARCH (2016)
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers
Elizabeth R. Kessler et al.
INVESTIGATIONAL NEW DRUGS (2016)
A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma
Sumera Rizvi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
Grazia Palomba et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma
Kulthida Vaeteewoottacharn et al.
TUMOR BIOLOGY (2016)
The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Sumera Rizvi et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Epidemiology and Risk Factors of Cholangiocarcinoma
Martha M. Kirstein et al.
VISCERAL MEDICINE (2016)
Epidemiology of cholangiocarcinoma
Annika Bergquist et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2015)
A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers
T. Ioka et al.
EUROPEAN JOURNAL OF CANCER (2015)
Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma
Takuji Okusaka et al.
HEPATOLOGY RESEARCH (2015)
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
Autumn J. McRee et al.
INVESTIGATIONAL NEW DRUGS (2015)
A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma
Lipika Goyal et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
HER2/neu-directed therapy for biliary tract cancer
Milind Javle et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma
David King et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2015)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Juan W. Valle et al.
LANCET ONCOLOGY (2015)
Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma
Panagiotis Paliogiannis et al.
MOLECULAR MEDICINE REPORTS (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Suppression of cancer relapse and metastasis by inhibiting cancer stemness
Youzhi Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Jean-Florian Guion-Dusserre et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Multiple molecular pathways in melanomagenesis: characterization of therapeutic targets
Giuseppe Palmieri et al.
FRONTIERS IN ONCOLOGY (2015)
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
A. Santoro et al.
ANNALS OF ONCOLOGY (2015)
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
S. Pant et al.
ANNALS OF ONCOLOGY (2014)
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
A. B. El-Khoueiry et al.
BRITISH JOURNAL OF CANCER (2014)
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
M. Moehler et al.
EUROPEAN JOURNAL OF CANCER (2014)
Desmoplastic Stroma and Cholangiocarcinoma: Clinical Implications and Therapeutic Targeting
Alphonse E. Sirica et al.
HEPATOLOGY (2014)
Hedgehog pathway as a potential treatment target in human cholangiocarcinoma
Dorothee Riedlinger et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2014)
Notch signaling and new therapeutic options in liver disease
Carola Maria Morell et al.
JOURNAL OF HEPATOLOGY (2014)
Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma
Nataliya Razumilava et al.
JOURNAL OF HEPATOLOGY (2014)
Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Sumera Rizvi et al.
SEMINARS IN LIVER DISEASE (2014)
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
J. K. Lee et al.
BRITISH JOURNAL OF CANCER (2013)
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Sumera Rizvi et al.
GASTROENTEROLOGY (2013)
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Daniela Sia et al.
GASTROENTEROLOGY (2013)
Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma
Mona El Khatib et al.
HEPATOLOGY (2013)
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
D. Sia et al.
ONCOGENE (2013)
Transforming Growth Factor β Neutralization Ameliorates Pre-Existing Hepatic Fibrosis and Reduces Cholangiocarcinoma in Thioacetamide-Treated Rats
Hong Ling et al.
PLOS ONE (2013)
Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology
Artur A. Belov et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
L. H. Jensen et al.
ANNALS OF ONCOLOGY (2012)
Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations
Woody Han et al.
CANCER LETTERS (2012)
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2012)
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Shahid A. Khan et al.
GUT (2012)
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
Anthony B. El-Khoueiry et al.
INVESTIGATIONAL NEW DRUGS (2012)
Cholangiocarcinomas can originate from hepatocytes in mice
Biao Fan et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes
Sayaka Sekiya et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
Jeeyun Lee et al.
LANCET ONCOLOGY (2012)
HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
Joshua Peck et al.
ONCOLOGY (2012)
Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma
Sirintip Boonjaraspinyo et al.
TUMOR BIOLOGY (2012)
Desmoplasia: A Response or a Niche?
Yves A. DeClerck
CANCER DISCOVERY (2012)
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
M. Miyamoto et al.
BRITISH JOURNAL OF CANCER (2011)
Cholangiocarcinoma-controversies and challenges
Tushar Patel
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
CHOLANGIOCARCINOMA - CURRENT TREATMENT OPTIONS
S. Friman
SCANDINAVIAN JOURNAL OF SURGERY (2011)
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
C. Bengala et al.
BRITISH JOURNAL OF CANCER (2010)
Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatment
Somchai Pinlaor et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Preclinical Assessment of Simultaneous Targeting of Epidermal Growth Factor Receptor (ERBB1) and ERBB2 as a Strategy for Cholangiocarcinoma Therapy
Zichen Zhang et al.
HEPATOLOGY (2010)
Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
Sam J. Lubner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
Birgit Gruenberger et al.
LANCET ONCOLOGY (2010)
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
Andrew X. Zhu et al.
LANCET ONCOLOGY (2010)
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K. Ramanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Cholangiocarcinoma
Stefania Mosconi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas
James E. Everhart et al.
GASTROENTEROLOGY (2009)
Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas
Nathalie Guedj et al.
JOURNAL OF HEPATOLOGY (2009)
Interaction of B7-H1 on Intrahepatic Cholangiocarcinoma Cells With PD-1 on Tumor-Infiltrating T Cells as a Mechanism of Immune Evasion
Yufu Ye et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment
Boris Blechacz et al.
HEPATOLOGY (2008)
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma
Alphonse E. Sirica
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Cholangiocarcinoma: A compact review of the literature
Yucel Ustundag et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2008)
N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding
Laurence Duchesne et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Phase II study of erlotinib in patients with advanced biliary cancer
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A comprehensive pathway map of epidermal growth factor receptor signaling
Kanae Oda et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
YH Shaib et al.
JOURNAL OF HEPATOLOGY (2004)
The Hedgehog response network: Sensors, switches, and routers
L Lum et al.
SCIENCE (2004)
Worldwide trends in mortality from biliary tract malignancies
T Patel
BMC CANCER (2002)
Identification of a new fibroblast growth factor receptor, FGFR5
M Sleeman et al.
GENE (2001)
Share Paper
